The New England Journal of Medicine

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

Congenital thrombotic thrombocytopenic purpura (TTP) results from severe hereditary deficiency of ADAMTS13. The efficacy and safety of recombinant ADAMTS13 and standard therapy (plasma-derived ...
Nasdaq

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital ...

cTTP is an Ultra-rare Blood Clotting Disorder Associated with Life-Threatening Acute Events and Debilitating Chronic Symptoms Takeda Continues 70-plus Year Legacy of Driving Innovation for the Rare ...
The American Journal of Managed Care

Management of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation. X. Long Zheng, MD, PhD, details the typical ...
Healio

Caplacizumab effective in acquired thrombotic thrombocytopenic purpura

Please provide your email address to receive an email when new articles are posted on . Patients with acquired thrombotic thrombocytopenic purpura experienced a faster normalization of platelet count ...
The American Journal of Managed Care

Unmet Need Remains in iTTP Treatment, but Caplacizumab Could Be Major Step Forward

A panel of experts suggests adding caplacizumab to the historic treatment of plasma exchange and immunosuppression could lead to significant improvement in outcomes for patients with immune-mediated ...
News Medical

MGH investigators use new drug to save the life of patient with immune thrombotic thrombocytopenic purpura

A team led by investigators from Massachusetts General Hospital, a founding member of the Mass General Brigham healthcare system, used a new drug to save the life of a patient with immune thrombotic ...
Nature

Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?

Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...
Business Wire

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover ...
Business Wire

U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) ...
Science Daily

New treatment option for the acute phase of the rare disease TTP

Thrombotic Thrombocytopenic Purpura (TTP) is a rare disorder caused by an enzyme deficiency. This can be heriditary or can be acquired as an autoimmune condition. Due to the associated excessive ...
The New England Journal of Medicine

Thrombotic Microangiopathy Associated with Interferon Beta

Shown are renal-biopsy specimens obtained from four patients receiving recombinant interferon beta therapy in South Scotland in whom thrombotic microangiopathy was diagnosed during an 18-month period ...